Amgen, Takeda And Millennium Provide Update On Phase 3 Trial Of Motesanib In Patients With Non Small Cell Lung Cancer

in

Amgen (Nasdaq: AMGN) and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited (TSE: 4052), announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC).